Date: 2013-04-11
Type of information: Presentation of results at a congress
phase: preclinical studies
Announcement: presentation of results at the Molecular Pattern Recognition Receptors meeting and the American Association for Cancer Research (\
Company: Innate Pharma (France)
Product: IPH33
Action mechanism:
Disease:
Therapeutic area: Inflammatory diseases
Country:
Trial details:
Latest
news: * On April 12, 2013, Innate Pharma, the innate immunity company developing first-in-class drugs for cancer and inflammatory diseases, has announces that new preclinical data for IPH33 proprietary program were presented at the Molecular Pattern Recognition Receptors meeting and the American Association for Cancer Research (AACR) annual meeting.
Dr Morel, Chief Business Officer of Innate Pharma, presented \"Therapeutic Antibody against Toll-Like Receptor 3 for the Treatment of Inflammation\", a comprehensive review of the IPH33 program. Key conclusions are that humanized anti-TLR3 antibodies generated by Innate Pharma, following specific internalization in TLR3-expressing cells, showed efficient blocking of TLR3 signaling, with high potency. A surrogate anti-mouse TLR3-blocking antibody has shown activity in murine models of chronic obstructive pulmonary disease and colitis. This activity compares favorably to approved anti-inflammatory agents.
Innate Pharma is validating this candidate for entry in regulatory preclinical development and intends to partner the further development of this program.
